Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Obstructive Lung Diseases

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 149 articles: HTML format

Single Articles

October 2025
1. HOWELL I, Mahdi M, Mahmood HR, Bermejo-Sanchez L, et al
   Exhaled nitric oxide (FeNO) and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Ralpha therapy: a prospective observational study.
   Eur Respir J. 2025 Oct 9:2501229. doi: 10.1183/13993003.01229-2025.
   PubMed    
   
   
   
2. LEUNG C, Leung JM, Sin DD
   Reply to: Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD.
   Eur Respir J. 2025;66:2501584.
   PubMed    
   
   
   
3. SUN W
   Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD.
   Eur Respir J. 2025;66:2501403.
   PubMed    
   
   
   
4. RICHARDSON H, Alferes De Lima Headley D, Clarke C, Veluchamy A, et al
   The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC).
   Eur Respir J. 2025;66:2500287.
   PubMed     Abstract available
   
   
   
5. ZHU Z, Liu C, Ober C, Camargo CA Jr, et al
   Gene-environment interaction at 17q12-q21 locus and its role in asthma pathogenesis.
   Eur Respir J. 2025;66:2501232.
   PubMed    
   
   
   
6. ANNESI-MAESANO I, Bayram H, Cecchi L, Croft D, et al
   Natural disasters and respiratory health.
   Eur Respir J. 2025;66:2402563.
   PubMed     Abstract available
   
   
   September 2025
7. CHALMERS JD, Haworth CS, Flume P, Long MB, et al
   European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis.
   Eur Respir J. 2025 Sep 28:2501126. doi: 10.1183/13993003.01126-2025.
   PubMed     Abstract available
   
   
   
8. DAVIES TJ, Pavord ID
   Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?
   Eur Respir J. 2025;66:2501321.
   PubMed    
   
   
   
9. 
   ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis.
   Eur Respir J. 2025;66:25E6603.
   PubMed    
   
   
   
10. RASTODER E, Sivapalan P, Hedsund C, Kamstrup P, et al
    Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome.
    Eur Respir J. 2025;66:2500169.
    PubMed     Abstract available
    
    
    August 2025
11. LEE B, Wong E, Tan T, Rupani H, et al
    Pregnancy, asthma and exacerbations: a population-based cohort.
    Eur Respir J. 2025 Aug 28:2501327. doi: 10.1183/13993003.01327-2025.
    PubMed     Abstract available
    
    
    
12. BACOPANOS E, Forrester DL, Girdler E, Gonnelli F, et al
    The increasing burden of bronchiectasis in the United Kingdom.
    Eur Respir J. 2025 Aug 28:2500909. doi: 10.1183/13993003.00909-2025.
    PubMed    
    
    
    
13. NARAYANA JK, Koo Wei Ling Y, Mac Aogain M, Chotirmall SH, et al
    Characterizing research trends in bronchiectasis through AI-powered analytics.
    Eur Respir J. 2025 Aug 28:2500894. doi: 10.1183/13993003.00894-2025.
    PubMed     Abstract available
    
    
    
14. WILKINSON TMA, Akuthota P
    CompEx Asthma: is it time for a change in clinical trials?
    Eur Respir J. 2025 Aug 21:2500470. doi: 10.1183/13993003.00470-2025.
    PubMed    
    
    
    
15. MANGALICK K, Segal LN
    Just like good wine, European bronchiectasis deserves regional denominations.
    Eur Respir J. 2025;66:2501020.
    PubMed    
    
    
    July 2025
16. CHALMERS JD, Mall MA, Nielsen KG, Chang AB, et al
    Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.
    Eur Respir J. 2025 Jul 10:2500081. doi: 10.1183/13993003.00081-2025.
    PubMed     Abstract available
    
    
    
17. LIU KY, Sie JJ, Gao Y, Lo YL, et al
    Functional sequence variants of intergenic long non-coding RNA on Chromosome 17q21 are associated with asthma.
    Eur Respir J. 2025 Jul 3:2500847. doi: 10.1183/13993003.00847-2025.
    PubMed     Abstract available
    
    
    
18. KHALAILI L, Aliberti S, Viligorska K, Blasi F, et al
    Greater disease severity in adults with paediatric-onset versus adult-onset bronchiectasis: a multicenter EMBARC registry study.
    Eur Respir J. 2025 Jul 3:2500665. doi: 10.1183/13993003.00665-2025.
    PubMed     Abstract available
    
    
    
19. SINGH D, Guller P, Reid F, Doffman S, et al
    A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
    Eur Respir J. 2025;66:2402231.
    PubMed     Abstract available
    
    
    
20. MENON L, Blakey J, Ramakrishnan S
    Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500685.
    PubMed    
    
    
    
21. CELIS-PRECIADO C, Lemaire-Paquette S, Lachapelle P, Couillard S, et al
    Reply to: Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500949.
    PubMed    
    
    
    
22. DELGADO-ORTIZ L, Buekers J, Chynkiamis N, Demeyer H, et al
    How do people with COPD walk? A European study on digitally measured real-world gait.
    Eur Respir J. 2025;66:2402303.
    PubMed     Abstract available
    
    
    June 2025
23. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
    Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
    Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
    PubMed     Abstract available
    
    
    May 2025
24. THNG KX, Tiew PY, Mac Aogain M, Narayana JK, et al
    Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study.
    Eur Respir J. 2025 May 22:2500054. doi: 10.1183/13993003.00054-2025.
    PubMed     Abstract available
    
    
    
25. WU SM, Chen KY, Chuang HC, Ho SC, et al
    Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling.
    Eur Respir J. 2025 May 22:2401610. doi: 10.1183/13993003.01610-2024.
    PubMed     Abstract available
    
    
    
26. GIRAULT A, Le A, Gonsard A, Abou Taam R, et al
    ChatGPT and Other Large Language Models for Parents' Questions About Childhood Asthma: A Comparative Study.
    Eur Respir J. 2025 May 15:2500254. doi: 10.1183/13993003.00254-2025.
    PubMed    
    
    
    
27. LEUNG C, Park HY, Li X, Koelwyn GJ, et al
    Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response.
    Eur Respir J. 2025;65:2401875.
    PubMed     Abstract available
    
    
    
28. DARIE AM, Grize L, Jahn K, Salina A, et al
    Preventing oxygen desaturation during bronchoscopy in COPD patients using high-flow oxygen versus standard management: the randomised controlled PROSA 2 trial.
    Eur Respir J. 2025;65:2401586.
    PubMed     Abstract available
    
    
    
29. BUSSE WW, O'Byrne PM
    Are systemic corticosteroids needed for all asthma exacerbations?
    Eur Respir J. 2025;65:2500370.
    PubMed    
    
    
    April 2025
30. SHI MX, Guo SJ, Yue JQ, Zhang XX, et al
    Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis.
    Eur Respir J. 2025 Apr 23:2500518. doi: 10.1183/13993003.00518-2025.
    PubMed    
    
    
    
31. YANG F, Bossios A
    Who really responds to asthma biologics? The clue lies in the journey before treatment.
    Eur Respir J. 2025;65:2500044.
    PubMed    
    
    
    
32. SAFERALI A, Wienecke AN, Xu Z, Liu T, et al
    Characterisation of a COPD-associated nephronectin (NPNT) functional splicing genetic variant in human lung tissue via long-read sequencing.
    Eur Respir J. 2025;65:2401407.
    PubMed     Abstract available
    
    
    
33. 
    "Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways." B. Stikker, L. Trap, B. Sedaghati-Khayat, et al. Eur Respir J 2024; 64: 2302059.
    Eur Respir J. 2025;65:2352059.
    PubMed    
    
    
    
34. KOURID MI, Couillard S
    Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
    Eur Respir J. 2025;65:2500153.
    PubMed    
    
    
    
35. HAMADA Y, Thomas D, Gibson PG
    Reply to: Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500516.
    PubMed    
    
    
    
36. 
    "Advancing patient-centred care in measuring response to biologics in severe asthma." Vanesa Bellou. Eur Respir J 2025; 65: 2402113.
    Eur Respir J. 2025;65:2452113.
    PubMed    
    
    
    
37. TAKEFUJI Y
    Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500423.
    PubMed    
    
    
    March 2025
38. NEW BJ, Chalmers JD
    Unbreak my heart: macrolide cardiovascular benefits and safety in bronchiectasis.
    Eur Respir J. 2025;65:2500045.
    PubMed    
    
    
    
39. BELLOU V
    Advancing patient-centred care in measuring response to biologics in severe asthma.
    Eur Respir J. 2025;65:2402113.
    PubMed    
    
    
    February 2025
40. BOURDIN A, Nogue E, Matzner-Lober E, Malafaye N, et al
    What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study.
    Eur Respir J. 2025 Feb 27:2402264. doi: 10.1183/13993003.02264-2024.
    PubMed    
    
    
    
41. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
    Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
    Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
    PubMed     Abstract available
    
    
    
42. SINGH D, Stockley R, Anzueto A, Agusti A, et al
    GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.
    Eur Respir J. 2025;65:2401603.
    PubMed     Abstract available
    
    
    
43. WADE RC, Martinez FJ, Criner GJ, Tombs L, et al
    ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.
    Eur Respir J. 2025;65:2400171.
    PubMed     Abstract available
    
    
    
44. MAILHOT-LAROUCHE S, Busby J, Couillard S
    Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402057.
    PubMed    
    
    
    
45. MARTIN N, Wechsler ME, Brightling CE
    Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402434.
    PubMed     Abstract available
    
    
    January 2025
46. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    PubMed     Abstract available
    
    
    
47. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    PubMed     Abstract available
    
    
    
48. ARBIV OA, Quon BS
    Disarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis.
    Eur Respir J. 2025;65:2401804.
    PubMed    
    
    
    
49. KHEDOE PPSJ, van 't Wout EFA
    Buddy, bystander or betrayer: B cells in lymphoid aggregates in AATD emphysema.
    Eur Respir J. 2025;65:2402163.
    PubMed    
    
    
    
50. NOLASCO S, Mukherjee M, Nair P
    Trajectories of responses to mepolizumab in severe asthma.
    Eur Respir J. 2025;65:2402023.
    PubMed    
    
    
    
51. 
    ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma.
    Eur Respir J. 2025;65:25E6501.
    PubMed    
    
    
    
52. AMEGADZIE JE, Mehareen J, Khakban A, Joshi P, et al
    20-year trends in excess costs of COPD.
    Eur Respir J. 2025;65:2400516.
    PubMed     Abstract available
    
    
    December 2024
53. GUO Y, Donnelly LE
    Identification of an emphysema-specific ATII cell: a step towards understanding impaired lung regeneration in COPD?
    Eur Respir J. 2024;64:2401741.
    PubMed    
    
    
    
54. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    PubMed    
    
    
    
55. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    PubMed    
    
    
    
56. BODDULURI S, Nakhmani A, Kizhakke Puliyakote AS, Reinhardt JM, et al
    Airway tapering in COPD.
    Eur Respir J. 2024;64:2400191.
    PubMed     Abstract available
    
    
    
57. MAURAT E, Raasch K, Leipold AM, Henrot P, et al
    A novel in vitro tubular model to recapitulate features of distal airways: the bronchioid.
    Eur Respir J. 2024;64:2400562.
    PubMed     Abstract available
    
    
    
58. HERMANN EA, Sun Y, Hoffman EA, Allen NB, et al
    Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study.
    Eur Respir J. 2024;64:2400820.
    PubMed     Abstract available
    
    
    
59. WENG C, Zhao Y, Song M, Shao Z, et al
    Mosaic loss of chromosome Y, tobacco smoking and risk of age-related lung diseases: insights from two prospective cohorts.
    Eur Respir J. 2024;64:2400968.
    PubMed     Abstract available
    
    
    November 2024
60. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    PubMed    
    
    
    
61. GUO R, Wat D, Ho S, Lam M, et al
    Cardiovascular Benefits and Safety Profile of Macrolide Maintenance Therapy in Patients with Bronchiectasis.
    Eur Respir J. 2024 Nov 27:2401574. doi: 10.1183/13993003.01574-2024.
    PubMed     Abstract available
    
    
    
62. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    PubMed     Abstract available
    
    
    
63. CRINER GJ, Gayen S, Zantah M, Dominguez Castillo E, et al
    Clinical review of non-invasive ventilation.
    Eur Respir J. 2024;64:2400396.
    PubMed     Abstract available
    
    
    
64. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    PubMed    
    
    
    
65. TIEW PY, Leung JM, Mac Aogain M, Johal P, et al
    Residential exposure to Aspergillus spp. is associated with exacerbations in COPD.
    Eur Respir J. 2024;64:2400907.
    PubMed     Abstract available
    
    
    October 2024
66. CHALMERS JD, Mall MA, Chotirmall SH, O'Donnell AE, et al
    Targeting neutrophil serine proteases in bronchiectasis.
    Eur Respir J. 2024 Oct 28:2401050. doi: 10.1183/13993003.01050-2024.
    PubMed     Abstract available
    
    
    
67. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    PubMed     Abstract available
    
    
    
68. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    PubMed     Abstract available
    
    
    
69. ROJAS-QUINTERO J, Ochsner SA, Lee HS, Cong C, et al
    Skewed adaptive immune responses are involved in AATD emphysema.
    Eur Respir J. 2024 Oct 10:2400839. doi: 10.1183/13993003.00839-2024.
    PubMed    
    
    
    
70. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    PubMed    
    
    
    
71. HOEPER MM
    Selexipag: still looking for its place.
    Eur Respir J. 2024;64:2401560.
    PubMed    
    
    
    
72. CABRERA LOPEZ C, Figueira-Goncalves JM
    Previous exacerbations in newly diagnosed COPD patients: do they matter?
    Eur Respir J. 2024;64:2401019.
    PubMed    
    
    
    
73. HALPIN DMG, Healey H, Skinner D, Carter V, et al
    Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.
    Eur Respir J. 2024;64:2302240.
    PubMed     Abstract available
    
    
    September 2024
74. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    PubMed     Abstract available
    
    
    
75. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
76. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    PubMed     Abstract available
    
    
    
77. CHALMERS JD, Shteinberg M, Mall MA, O'Donnell AE, et al
    Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF(R), a Phase II randomised, double-blind, placebo-controlled, dose-finding study.
    Eur Respir J. 2024 Sep 10:2401551. doi: 10.1183/13993003.01551-2024.
    PubMed     Abstract available
    
    
    
78. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    PubMed    
    
    
    
79. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    PubMed     Abstract available
    
    
    
80. BACKMAN H
    10 pack-years of smoking: not the magic number for COPD risk and prognosis.
    Eur Respir J. 2024;64:2401230.
    PubMed    
    
    
    
81. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    PubMed    
    
    
    
82. COLAK Y, Lokke A, Marott JL, Lange P, et al
    Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study.
    Eur Respir J. 2024;64:2400314.
    PubMed     Abstract available
    
    
    
83. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    PubMed    
    
    
    
84. YILDIRIM AO, Conlon TM, Adcock IM, Gosens R, et al
    COPD-iNET: a call to the lung community for action to combat the global epidemic of COPD.
    Eur Respir J. 2024;64:2400921.
    PubMed    
    
    
    August 2024
85. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    PubMed    
    
    
    
86. SHLOBIN OA, Adir Y, Barbera JA, Cottin V, et al
    Pulmonary hypertension associated with lung diseases.
    Eur Respir J. 2024 Aug 29:2401200. doi: 10.1183/13993003.01200-2024.
    PubMed     Abstract available
    
    
    
87. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    PubMed     Abstract available
    
    
    
88. HU Y, Hu Q, Ansari M, Riemondy K, et al
    Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.
    Eur Respir J. 2024 Aug 15:2302071. doi: 10.1183/13993003.02071-2023.
    PubMed     Abstract available
    
    
    
89. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    PubMed    
    
    
    
90. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    PubMed     Abstract available
    
    
    
91. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    PubMed    
    
    
    
92. AL SA'IDI L, Berton DC, Neder JA
    The 2022 ERS/ATS z-score classification to grade airflow obstruction: relationship with exercise outcomes across the spectrum of COPD severity.
    Eur Respir J. 2024;64:2301960.
    PubMed    
    
    
    
93. BROWN JS
    The importance of airway IL-1beta in patients with bronchiectasis.
    Eur Respir J. 2024;64:2400997.
    PubMed    
    
    
    
94. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    PubMed    
    
    
    
95. ALIBERTI S, Chalmers JD
    Reply to: Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2401390.
    PubMed    
    
    
    
96. YAMAMOTO S, Ishikawa H, Takeda K, Kawashima M, et al
    Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2400745.
    PubMed    
    
    
    July 2024
97. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    PubMed     Abstract available
    
    
    
98. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    PubMed    
    
    
    
99. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    PubMed    
    
    
    
100. LU J, Wang Z
     Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
     Eur Respir J. 2024;64:2400628.
     PubMed    
     
     
     
101. 
     "Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)." A. Spinou, B. Hererro-Cortina, S. Aliberti, et al. Eur Respir J 2024; 63: 2301689.
     Eur Respir J. 2024;64:2351689.
     PubMed    
     
     
     June 2024
102. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
     Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
     Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
     PubMed     Abstract available
     
     
     
103. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
     Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
     Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
     PubMed     Abstract available
     
     
     
104. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
     IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
     Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
     PubMed    
     
     
     
105. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
     Missing airways, ventilation defects and conductive airway physiology in asthma.
     Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
     PubMed    
     
     
     
106. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
     OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
     Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
     PubMed     Abstract available
     
     
     
107. SPINOU A, Almagro M, Harris B, Boyd J, et al
     Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey.
     Eur Respir J. 2024 Jun 6:2301504. doi: 10.1183/13993003.01504-2023.
     PubMed    
     
     
     
108. KOVACS G, Humbert M
     Primum non nocere, secundum cavere, tertium sanare: lessons on the management of pulmonary hypertension associated with COPD.
     Eur Respir J. 2024;63:2400765.
     PubMed    
     
     
     
109. CAI J, Vonder M, Du Y, Pelgrim GJ, et al
     Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.
     Eur Respir J. 2024;63:2301736.
     PubMed     Abstract available
     
     
     
110. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
     Clinical remission with biologic therapies in severe asthma: a matter of definition.
     Eur Respir J. 2024;63:2400160.
     PubMed     Abstract available
     
     
     
111. BEASLEY R, Noble J, Weatherall M
     The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
     Eur Respir J. 2024;63:2400523.
     PubMed     Abstract available
     
     
     
112. IMTIAZ A, King J, Holmes S, Gupta A, et al
     ChatGPT versus Bing: a clinician assessment of the accuracy of AI platforms when responding to COPD questions.
     Eur Respir J. 2024;63:2400163.
     PubMed    
     
     
     May 2024
113. PEREA L, Bottier M, Cant E, Richardson H, et al
     Airway IL-1beta is related to disease severity and mucociliary function in bronchiectasis.
     Eur Respir J. 2024 May 29:2301966. doi: 10.1183/13993003.01966-2023.
     PubMed     Abstract available
     
     
     
114. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
     Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
     Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
     PubMed     Abstract available
     
     
     
115. NATHAN SD, Argula R, Trivieri MG, Aziz S, et al
     Inhaled Treprostinil in Pulmonary Hypertension Associated with COPD: PERFECT study results.
     Eur Respir J. 2024 May 29:2400172. doi: 10.1183/13993003.00172-2024.
     PubMed     Abstract available
     
     
     
116. CHOI H, McShane PJ, Aliberti S, Chalmers JD, et al
     Bronchiectasis management in adults: state of the art and future directions.
     Eur Respir J. 2024 May 23:2400518. doi: 10.1183/13993003.00518-2024.
     PubMed     Abstract available
     
     
     
117. LIU T, Prescott WG, Zhou X
     Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
     Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
     PubMed     Abstract available
     
     
     
118. ELBEHAIRY AF, Marshall H, Naish JH, Wild JM, et al
     Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes.
     Eur Respir J. 2024;63:2301010.
     PubMed     Abstract available
     
     
     
119. RAMAKRISHNAN S, Montgomery B, Pavord ID
     Blood eosinophils and lung function loss: from passive prediction to active prevention?
     Eur Respir J. 2024;63:2400812.
     PubMed    
     
     
     
120. BUSH A, Randerath W, Roche N
     As needed ICS/formoterol: not all of Europe is equal.
     Eur Respir J. 2024;63:2400408.
     PubMed    
     
     
     
121. HONG YS, Park HY, Ryu S, Shin SH, et al
     The association of blood eosinophil counts and FEV(1) decline: a cohort study.
     Eur Respir J. 2024;63:2301037.
     PubMed     Abstract available
     
     
     
122. POLVERINO F, Sin DD
     Type 2 airway inflammation in COPD.
     Eur Respir J. 2024;63:2400150.
     PubMed     Abstract available
     
     
     April 2024
123. SPINOU A, Hererro-Cortina B, Aliberti S, Goeminne PC, et al
     Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
     Eur Respir J. 2024 Apr 12:2301689. doi: 10.1183/13993003.01689-2023.
     PubMed     Abstract available
     
     
     
124. HATTER L, Holliday M, Eathorne A, Bruce P, et al
     The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
     Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
     PubMed     Abstract available
     
     
     
125. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
     Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
     Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
     PubMed     Abstract available
     
     
     
126. COTTIN V
     Combined pulmonary fibrosis and emphysema syndrome: the age of majority.
     Eur Respir J. 2024;63:2400353.
     PubMed    
     
     
     
127. KRISHNAN JA, Buhl R
     As-needed ICS/formoterol or as-needed SABA in mild asthma?
     Eur Respir J. 2024;63:2302308.
     PubMed    
     
     
     
128. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
     Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
     Eur Respir J. 2024;63:2400395.
     PubMed    
     
     
     
129. 
     "Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis." M.O. Wielputz and M.A. Mall. Eur Respir J 2024; 63: 2400234.
     Eur Respir J. 2024;63:2450234.
     PubMed    
     
     
     
130. TANG RD, Yue JQ, Guan WJ
     Sputum colour as a simplified effective biomarker for clinical assessment of bronchiectasis.
     Eur Respir J. 2024;63:2400152.
     PubMed    
     
     
     
131. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
     Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
     Eur Respir J. 2024;63:2301568.
     PubMed     Abstract available
     
     
     
132. ALIBERTI S, Ringshausen FC, Dhar R, Haworth CS, et al
     Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
     Eur Respir J. 2024;63:2301554.
     PubMed     Abstract available
     
     
     
133. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
     Airway remodelling in asthma and the epithelium: on the edge of a new era.
     Eur Respir J. 2024;63:2301619.
     PubMed     Abstract available
     
     
     
134. BLOOM CI
     Reply: Asthma and cardiovascular disease: the strength of triangulation.
     Eur Respir J. 2024;63:2400554.
     PubMed    
     
     
     
135. TATTERSALL MC, Gangnon RE, Jarjour NN
     Asthma and cardiovascular disease: embracing disease heterogeneity is required.
     Eur Respir J. 2024;63:2400469.
     PubMed    
     
     
     
136. 
     ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
     Eur Respir J. 2024;63:24E6304.
     PubMed    
     
     
     March 2024
137. LIU T, Liu S, Rui X, Cao Y, et al
     Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
     Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
     PubMed     Abstract available
     
     
     
138. LUO RG, Wu YF, Lu HW, Weng D, et al
     Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
     Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
     PubMed     Abstract available
     
     
     
139. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
     The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
     Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
     PubMed     Abstract available
     
     
     
140. JIN Z, Wang G
     Some future directions for genome-wide association studies of preserved ratio impaired spirometry.
     Eur Respir J. 2024;63:2400142.
     PubMed    
     
     
     
141. 
     "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
     Eur Respir J. 2024;63:2351788.
     PubMed    
     
     
     
142. 
     "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
     Eur Respir J. 2024;63:1852422.
     PubMed    
     
     
     
143. WIELPUTZ MO, Mall MA
     Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
     Eur Respir J. 2024;63:2400234.
     PubMed    
     
     
     
144. BOS S, Murray J, Marchetti M, Cheng GS, et al
     ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
     Eur Respir J. 2024;63:2301727.
     PubMed     Abstract available
     
     
     February 2024
145. COHEN R, Shteinberg M
     Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
     Eur Respir J. 2024;63:2400068.
     PubMed    
     
     
     
146. WANG T, Duan W, Jia X, Huang X, et al
     Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
     Eur Respir J. 2024;63:2301720.
     PubMed     Abstract available
     
     
     
147. VERLEDEN SE, Lapperre TS, Snoeckx A, Wen W, et al
     Interalveolar pore morphology in (pre-)COPD stages and associations with small airways.
     Eur Respir J. 2024;63:2302263.
     PubMed    
     
     
     
148. 
     ERJ Podcast February 2024: Beetroot juice and cardiovascular risk in COPD.
     Eur Respir J. 2024;63:24E6302.
     PubMed    
     
     
     August 2023
149. 
     ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
     Eur Respir J. 2024;64:24E6402.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Obstructive Lung Diseases is free of charge.